ArticleNucleic acids research2014
CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages.
Article in Nucleic acids research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 179 citations in OpenAlex.
- Rapid, expression-free bacteriophage-based specific detection of target bacteria by conditional release of encapsidated reporter molecules.Bioengineering & translational medicine · 2026Article
- Scarless one-tube genome assemblyRSC chemical biology · 2026Article
- Phage satellites induced by virulent phages are mobilized by natural competence leading to phage resistance in a new host.Nature communications · 2026Article
- Application and Research Prospects of CRISPR/Cas Gene Editing Technology in Lactic Acid Bacteria.Microorganisms · 2026Review
- Bacteriophages as Therapeutic Agents for Pulmonary Infections: From Biological Principles to Clinical Applications.Pharmaceutics · 2026Review
- Engineered Bacteriophages: A Next-Generation Platform for Precision Antimicrobials and Therapeutics.Viruses · 2026Review
- A fully synthetic Golden Gate assembly system for engineering aProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Recent Advances in Endolysin Engineering.Antibiotics (Basel, Switzerland) · 2025Review
- Article
- A phage-encoded anti-CRISPR protein co-opts host enolase to prevent type III CRISPR immunity.Nature microbiology · 2025Article
- Rapid detection ofActa biochimica et biophysica Sinica · 2025Article
- Lung virome convergence precedes hospital-acquired pneumonia in intubated critically ill patients.Cell reports. Medicine · 2025Article
- CRISPR-Cas10-Assisted Structural Modification of StaphylococcalACS synthetic biology · 2025Article
- Synthetic Biology-Based Engineering Living Therapeutics for Antimicrobial Application.Exploration (Beijing, China) · 2025Article
- Genetic engineering of bacteriophage S16 for Salmonella separation, concentration, and detection.Analytical and bioanalytical chemistry · 2025Article
- Review
- Article
- Bacteriophages as Targeted Therapeutic Vehicles: Challenges and Opportunities.Bioengineering (Basel, Switzerland) · 2025Review
- Comprehensive Genomic Analysis ofMicroorganisms · 2025Article
- Phage therapy for Klebsiella pneumoniae: Understanding bacteria-phage interactions for therapeutic innovations.PLoS pathogens · 2025Review
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophages are now widely recognized as major players in a wide variety of ecosystems. Novel genes are often identified in newly isolated phages as well as in environmental metavirome studies. Most of these novel viral genes have unknown functions but appear to be coding for small, non-structural proteins. To understand their biological role, very efficient genetic tools are required to modify them, especially in the genome of virulent phages. We first show that specific point mutations and large deletions can be engineered in the genome of the virulent phage 2972 using the Streptococcus thermophilus CRISPR-Cas Type II-A system as a selective pressure to increase recombination efficiencies. Of significance, all the plaques tested contained recombinant phages with the desired mutation. Furthermore, we show that the CRISPR-Cas engineering system can be used to efficiently introduce a functional methyltransferase gene into a virulent phage genome. Finally, synthetic CRISPR bacteriophage insensitive mutants were constructed by cloning a spacer-repeat unit in a low-copy vector illustrating the possibility to target multiple regions of the phage genome. Taken together, this data shows that the CRISPR-Cas system is an efficient and adaptable tool for editing the otherwise intractable genomes of virulent phages and to better understand phage-host interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.